Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 172.86
- Piotroski Score 4.00
- Grade Buy
- Symbol (VKTX)
- Company Viking Therapeutics, Inc.
- Price $67.18
- Changes Percentage (6.4%)
- Change $4.04
- Day Low $62.50
- Day High $67.32
- Year High $99.41
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $110.50
- High Stock Price Target $138.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -60.86
- Forward P/E Ratio -60.86
- P/E Growth -60.86
- Net Income $-85,895,000
Income Statement
Quarterly
Annual
Latest News of VKTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ...
Brian Lian, President and CEO, discusses plans for monthly dosing, combination testing with amylin, safety expectations for higher doses, and the value split between subcutaneous and oral forms of VK2...
By Yahoo! Finance | 1 week ago -
With 74% institutional ownership, Viking Therapeutics, Inc. (NASDAQ:VKTX) is a favorite amongst the big guns
In Viking Therapeutics, 16 investors hold a majority stake of 51%. Institutions are the largest shareholders with 74% ownership, influencing the company's performance. Insider ownership aligns with bo...
By Yahoo! Finance | 3 weeks ago -
Viking Therapeutics, Inc. (VKTX): A Hot Stock to Buy Now
A list of hot stocks includes Viking Therapeutics, Inc. amid market pressures like the ILA port strike and Hurricane Helene's impact. Analysts favor VKTX for its promising drug trials, with an 83.87% ...
By Yahoo! Finance | 4 weeks ago
